
-
Mereo BioPharma NasdaqCM:MREO Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Location: One Cavendish Place, London, W1G 0QF, United Kingdom | Website: https://www.mereobiopharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.695B
Cash
62.48M
Avg Qtr Burn
-8.293M
Short % of Float
1.41%
Insider Ownership
0.96%
Institutional Own.
69.74%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Setrusumab (UX143) Details Osteogenesis imperfecta | Phase 2/3 Update | |
Alvelestat (MPH-966) Details Bronchiolitis Obliterans Syndrome | Phase 2 Data readout | |
Alvelestat (MPH-966) Details Severe alpha-1 antitrypsin deficiency, Lung disease | Phase 2 Update | |
Etigilimab Details Cancer, Ovarian cancer | Phase 1/2 Data readout | |
Etigilimab (MPH-313) + Nivolumab Details Cancer, Solid tumor/s | Phase 1b Update | |
Alvelestat (MPH-966) Details COVID-19 | Failed Discontinued |